Association of prior stroke with cognitive function and cognitive impairment: a population-based study.

BACKGROUND Defining the nature of the contribution of stroke to cognitive impairment remains challenging. OBJECTIVE To describe associations between stroke history, APOE genotype, and subtypes of mild cognitive impairment (MCI). METHODS We randomly selected residents from Olmsted County, Minnesota, aged 70 to 89 years on October 1, 2004, and invited eligible subjects without documented dementia to participate. Participants (n = 2050) were evaluated through an informant interview, a neurological evaluation, and neuropsychological testing. Neuropsychological testing included 9 tests to assess memory, attention, executive function, visuospatial cognition, and language. Subjects were diagnosed by consensus as cognitively normal or as having MCI (either amnestic or nonamnestic) or dementia. A history of stroke was obtained from the subjects and confirmed in their medical records. We computed the odds ratios (ORs) for a clinical diagnosis of MCI or for scoring in the lowest quartile on each cognitive domain. RESULTS There were 1640 cognitively normal subjects and 329 subjects with MCI: 241 with amnestic MCI and 88 with nonamnestic MCI. In fully adjusted models with only subjects without dementia, a history of stroke was associated with a higher OR of nonamnestic MCI (OR, 2.85; 95% confidence interval [CI], 1.61-5.04) than amnestic MCI (OR, 1.77; 95% CI, 1.14-2.74). A history of stroke was also associated with impaired function in each cognitive domain except memory. The association was strongest for attention and executive function (OR, 2.48; 95% CI, 1.73-3.53). APOE epsilon4 genotype was associated only with amnestic MCI and with impaired memory function. CONCLUSIONS In this population-based sample of persons without dementia, a history of stroke was particularly associated with nonamnestic MCI and impairment in nonmemory cognition. The APOE epsilon4 genotype was associated with memory impairment and amnestic MCI.

[1]  R. Petersen,et al.  Coronary heart disease is associated with non-amnestic mild cognitive impairment , 2010, Neurobiology of Aging.

[2]  V. Pankratz,et al.  Association of duration and severity of diabetes mellitus with mild cognitive impairment. , 2008, Archives of neurology.

[3]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[4]  V. Hachinski,et al.  Joint effect of stroke and APOE 4 on dementia risk , 2008, Neurology.

[5]  P. Mecocci,et al.  Vascular Risk Factors in Mild Cognitive Impairment Subtypes , 2007, Dementia and Geriatric Cognitive Disorders.

[6]  W. Jagust,et al.  Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. , 2007, Brain : a journal of neurology.

[7]  Chris Zarow,et al.  Cognitive impact of subcortical vascular and Alzheimer's disease pathology , 2006, Annals of neurology.

[8]  B. Winblad,et al.  Cerebrovascular disease, APOE ϵ4 allele and cognitive decline in a cognitively normal population , 2006 .

[9]  R. Mayeux,et al.  Stroke and memory performance in elderly persons without dementia. , 2006, Archives of neurology.

[10]  Niels D Prins,et al.  Cerebral small-vessel disease and decline in information processing speed, executive function and memory. , 2005, Brain : a journal of neurology.

[11]  N. Schuff,et al.  Longitudinal volumetric MRI change and rate of cognitive decline , 2005, Neurology.

[12]  Michael Weiner,et al.  Effects of white matter lesions and lacunes on cortical function. , 2004, Archives of neurology.

[13]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[14]  H. C. Chui,et al.  White matter lesions impair frontal lobe function regardless of their location , 2004, Neurology.

[15]  J. M. Guralnik,et al.  The role of APOE-&egr;4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging , 2003 .

[16]  J. Bowler.  The concept of vascular cognitive impairment , 2002, Journal of the Neurological Sciences.

[17]  E. Kaplan,et al.  The Boston naming test , 2001 .

[18]  E. Corder,et al.  Stroke and Apolipoprotein E &egr;4 Are Independent Risk Factors for Cognitive Decline: A Population-Based Study , 2000, Stroke.

[19]  A. Hofman,et al.  Cerebral white matter lesions and cognitive function: The Rotterdam scan study , 2000, Annals of neurology.

[20]  P. Sachdev,et al.  Differentiation of vascular dementia from AD on neuropsychological tests , 1999, Neurology.

[21]  C. Burchfiel,et al.  Influence of myocardial infarction, coronary artery bypass surgery, and stroke on cognitive impairment in late life. , 1998, The American journal of cardiology.

[22]  E. Tangalos,et al.  Mayo's older Americans normative studies: category fluency norms. , 1998, Journal of clinical and experimental neuropsychology.

[23]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[24]  James A. Mortimer,et al.  Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .

[25]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[26]  E. Feskens,et al.  Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. , 1996, Stroke.

[27]  L. Melton,et al.  History of the Rochester Epidemiology Project. , 1996, Mayo Clinic proceedings.

[28]  D. Schaid,et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.

[29]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[30]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[31]  E. Tangalos,et al.  Mayo's Older Americans Normative Studies: Utility of corrections for age and education for the WAIS-R , 1992 .

[32]  James F. Malec,et al.  Mayo's older americans normative studies: WMS-R norms for ages 56 to 94 , 1992 .

[33]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[34]  P. Box.  Cerebral small-vessel disease and decline in information processing speed, executive function and memory , 2006 .

[35]  E. Tangalos,et al.  Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. , 1999, Neuropsychology.

[36]  E. Tangalos,et al.  Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO , 1996 .

[37]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .

[38]  E. Tangalos,et al.  Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 , 1992 .

[39]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[40]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .